InVivo Therapeutics Holdings Corp (OTCQB:NVIV)

Delayed Data
As of 1:58pm ET
 +0.04 / +1.36%
Today’s Change
Today|||52-Week Range
Industrial Services
Engineering & Construction

Company Description

Invivo Therapeutics Holdings Corp. is a medical device company, which develops and commercializes groundbreaking technologies for the treatment of spinal cord injuries. Its platform technologies focus on minimizing tissue damage sustained following acute injury and promoting neural plasticity of the spared healthy tissue, which may result in full or partial functional recovery. The company intends to leverage its primary platform technology to develop and commercialize three products: a biocompatible polymer scaffolding device to treat acute spinal cord injuries; a biocompatible hydrogel for local controlled release of methylprednisolone to treat acute spinal cord injuries and a biocompatible polymer scaffolding device seeded with autologous human neural stem cells to treat acute and chronic spinal cord injuries. Its additional applications of platform technologies include the potential treatment for, spinal cord injury following tumor removal, peripheral nerve damage, and postsurgical treatment of any transected nerve. The company was founded by Joseph P. Vacanti, Frank M. Reynolds and Robert Langer on November 28, 2005 and is headquartered in Cambridge, MA.

Contact Information

Invivo Therapeutics Holdings Corp.
One Kendall Square
Cambridge Massachusetts 02139
P:(617) 863-5500
Investor Relations:



Other institutional7.80%
Individual stakeholders18.74%
Mutual fund holders0.37%

Top Executives

Mark D. PerrinChief Executive Officer & Director
William D'AgostinoSenior Vice President-Operations
Steven F. McAllisterChief Financial Officer
Brian HessChief Technology Officer
Kristin NeffVP-Clinical Operations & Project Management

To view my watchlist

Not a member yet?

Sign up now for a free account